Top

Published in:

01-04-2008 | Clinical Review

Association of digestive organ disease with metabolic syndrome: role of adipocytokine and its molecular mechanisms

Author: Sumio Kawata

Published in: Clinical Journal of Gastroenterology | Issue 1/2008

Abstract

Recently, lifestyle-related disease due to excess nutrition and insufficient physical exercise has been increasing in developed countries, including Japan. Metabolic syndrome is related to visceral fat accumulation in individuals with upper body obesity. Adipose tissue is an endocrine organ that secretes adipocytokines such as adiponectin, leptin, and TNF-α. Obesity alters the secretion of adipocytokines, leading to insulin resistance and various other metabolic disorders. Little is known about how altered regulation of adipocytokines is related to the development and progression of digestive organ disease. Clarification of the mechanisms whereby such altered adipocytokine secretion participates in pathophysiology of digestive organ disease could lead to the development of preventive and therapeutic measures.

Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–21.PubMedCrossRef

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin ? Hepatology. 2004;40:46–54.PubMedCrossRef

Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–504.PubMedCrossRef

Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–7.PubMedCrossRef

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:111–8.CrossRef

Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 1999;91:1147–54.PubMedCrossRef

Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327–34.PubMed

Nishii T, Kono S, Abe H, Eguchi H, Shimazaki K, Hatano B, et al. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese men. Jpn J Cancer Res. 2001;92:836–40.PubMed

Davila JA, Morgan RO, Shaib Y, McGlynn KA, EI-Serag HB. Diabetes increased the risk of hepatocellular carcinoma in the United States: a population-based case control study. Gut. 2005;54:533–9.PubMedCrossRef

10.

EI-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.CrossRef

11.

Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–81.PubMedCrossRef

12.

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.PubMedCrossRef

13.

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.PubMedCrossRef

14.

15.

Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–7.PubMedCrossRef

16.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113–8.PubMedCrossRef

17.

Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol. 2007;47:556–64.PubMedCrossRef

18.

Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.PubMedCrossRef

19.

Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IFG-binding protein-3. J Natl Cancer Inst. 1999;91:620–5.PubMedCrossRef

20.

Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O’Dwyer ST. High-risk colorectal adenoma and serum insulin-like growth factors. Br J Surg. 2001;88:107–13.PubMedCrossRef

21.

Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127:1044–50.PubMedCrossRef

22.

Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, et al. Augmentation effect of postprandial hyperinsulinemia on growth of human hepatocellular carcinoma. Gut. 2002;51:100–4.PubMedCrossRef

23.

Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11:3642–6.PubMedCrossRef

24.

Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men. J Natl Cancer Inst. 2005;97:1688–94.PubMedCrossRef

25.

Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88:993–7.PubMedCrossRef

26.

Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.PubMed

27.

Mantozoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.CrossRef

28.

Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut. 2006;55:285–91.PubMedCrossRef

29.

Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.PubMedCrossRef

30.

Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase defective in Peutz- Jeghers sundrome. Nature. 1998;391:184–7.PubMedCrossRef

31.

Hardie DG, Hawley SA, Scott JW. AMP-activated protein development of the energy sensor concept. J Physiol. 2006;574:7–15.PubMedCrossRef

32.

Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283–93.PubMedCrossRef

33.

Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3.PubMedCrossRef

34.

Vogelstein B, Kinzler KW. Cancer genes and the pathway they control. Nat Med. 2004;10:789–99.PubMedCrossRef

35.

Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.PubMedCrossRef

36.

Hervouet E, Demont J, Pecina P, Vojtísková A, Houstek J, Simonnet H, et al. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial phosphorylation comples biogenesis. Carcinogenesis. 2005;26:531–9.PubMedCrossRef

37.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.PubMedCrossRef

38.

Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74.PubMedCrossRef

39.

Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, et al. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005;24:2391–402.PubMedCrossRef

40.

Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: Etiologic evidence and biological mechanisms. J Nutr. 2002;132:3456S–64S.PubMed

41.

IARC Working group: body weight and physical inactivity. IARC handbook of cancer prevention, vol 6. Lyon: IARC; 2002.

Title: Association of digestive organ disease with metabolic syndrome: role of adipocytokine and its molecular mechanisms
Author: Sumio Kawata
Publication date: 01-04-2008
Publisher: Springer Japan
Published in: Clinical Journal of Gastroenterology / Issue 1/2008
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-008-0001-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of digestive organ disease with metabolic syndrome: role of adipocytokine and its molecular mechanisms

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

A case of advanced colonic cancer that developed from residual laterally spreading tumor treated by piecemeal endoscopic mucosal resection

A case of congenital chloride diarrhea: information obtained through long-term follow-up with reduced electrolyte substitution

Review of diagnostic criteria for autoimmune pancreatitis; for establishment of international criteria

Eosinophilic gastroenteritis with eosinophilic infiltration of the gall bladder

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page